利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

11 条记录 (耗时 0.019 秒)

    EXTENDED RELEASE FORMULATION AND METHOD OF TREATING ADRENERGIC DYSREGULATION
    1.
    发明申请
    EXTENDED RELEASE FORMULATION AND METHOD OF TREATING ADRENERGIC DYSREGULATION 有权
    扩展释放配方和治疗ADRENERGIC DYSREGULATION的方法

    公开(公告)号：US20100063123A1

    公开(公告)日：2010-03-11

    申请号：US12615477

    申请日：2009-11-10

    申请人： Henry Joseph Horacek ,  Min Michael He ,  Moise A. Khayrallah

    发明人： Henry Joseph Horacek ,  Min Michael He ,  Moise A. Khayrallah

    IPC分类号： A61K31/415

    CPC分类号： A61K9/2018 ,  A61K9/2013 ,  A61K9/205 ,  A61K9/2054

    摘要： A composition and method of treating adrenergic dysregulation by administering the composition is disclosed, wherein the composition comprises a a2-adrenergic receptor agonist; a pharmaceutically acceptable hydrophilic matrix and a release-retardant of a metal alkyl sulfate. In embodiments, the composition provides a sustained release of the agonist, wherein after administration of the composition no more than once about every 12 hours to a subject having a steady state plasma concentration of the a2-adrenergic receptor agonist, the agonist's plasma concentration peak-to-trough ratio is no greater than about 1.9.

    摘要翻译： 公开了通过施用组合物治疗肾上腺素能失调的组合物和方法，其中所述组合物包含α1-肾上腺素能受体激动剂; 药学上可接受的亲水基质和金属烷基硫酸盐的释放阻滞剂。 在实施方案中，组合物提供激动剂的持续释放，其中在将组合物给予具有稳定的α2 - 肾上腺素能受体激动剂的稳态血浆浓度的受试者每12小时不超过一次的情况下，所述激动剂的血浆浓度峰 - 槽比不大于约1.9。

    Extended Release Formulation and Methods of Treating Adrenergic Dysregulation
    4.
    发明申请
    Extended Release Formulation and Methods of Treating Adrenergic Dysregulation 审中-公开
    延长释放制剂和治疗肾上腺素能调节的方法

    公开(公告)号：US20110245314A1

    公开(公告)日：2011-10-06

    申请号：US13082724

    申请日：2011-04-08

    申请人： Henry Joseph Horacek ,  Min Michael He ,  Moise A. Khayrallah

    发明人： Henry Joseph Horacek ,  Min Michael He ,  Moise A. Khayrallah

    IPC分类号： A61K31/4168 ,  A61P5/26

    CPC分类号： A61K9/2018 ,  A61K9/2013 ,  A61K9/205 ,  A61K9/2054

    摘要： A composition and method of treating adrenergic dysregulation by administering the composition is disclosed, wherein the composition comprises a α2-adrenergic receptor agonist; a pharmaceutically acceptable hydrophilic matrix and a release-retardant of a metal alkyl sulfate. In embodiments, the composition provides a sustained release of the agonist, wherein after administration of the composition no more than once about every 12 hours to a subject having a steady state plasma concentration of the α2-adrenergic receptor agonist, the agonist's plasma concentration peak-to-trough ratio is no greater than about 1.9.

    摘要翻译： 公开了通过施用组合物治疗肾上腺素能失调的组合物和方法，其中所述组合物包含α2-肾上腺素能受体激动剂; 药学上可接受的亲水基质和金属烷基硫酸盐的释放阻滞剂。 在实施方案中，组合物提供激动剂的持续释放，其中在将组合物给予具有稳定血浆浓度的α2-肾上腺素能受体激动剂的受试者不超过一次的情况下，每12小时给予一次激动剂的血浆浓度峰 - 槽比不大于约1.9。

    Extended Release Formulation and Method of Treating Adrenergic Dysregulation
    5.
    发明申请
    Extended Release Formulation and Method of Treating Adrenergic Dysregulation 审中-公开
    延长释放制剂和治疗肾上腺素能调节的方法

    公开(公告)号：US20100209510A1

    公开(公告)日：2010-08-19

    申请号：US12560648

    申请日：2009-09-16

    申请人： Henry Joseph Horacek ,  Min Michael He ,  Moise A. Khayrallah

    发明人： Henry Joseph Horacek ,  Min Michael He ,  Moise A. Khayrallah

    IPC分类号： A61K31/4168 ,  A61K9/10 ,  A61P9/12 ,  A61P9/00 ,  A61P9/04 ,  A61P25/02 ,  A61P3/10 ,  A61P25/18 ,  A61P25/00 ,  A61P25/14

    CPC分类号： A61K9/2018 ,  A61K9/2013 ,  A61K9/205 ,  A61K9/2054

    摘要： A composition and method of treating adrenergic dysregulation by administering the composition is disclosed, wherein the composition comprises a α2-adrenergic receptor agonist; a pharmaceutically acceptable hydrophilic matrix and a release-retardant of a metal alkyl sulfate. In embodiments, the composition provides a sustained release of the agonist, wherein after administration of the composition no more than once about every 12 hours to a subject having a steady state plasma concentration of the α2-adrenergic receptor agonist, the agonist's plasma concentration peak-to-trough ratio is no greater than about 1.9.

    摘要翻译： 公开了通过施用组合物治疗肾上腺素能失调的组合物和方法，其中所述组合物包含α2-肾上腺素能受体激动剂; 药学上可接受的亲水基质和金属烷基硫酸盐的释放阻滞剂。 在实施方案中，组合物提供激动剂的持续释放，其中在将组合物给予具有稳定血浆浓度的α2-肾上腺素能受体激动剂的受试者不超过一次的情况下，每12小时给予一次激动剂的血浆浓度峰 - 槽比不大于约1.9。

    Extended Release Formulation and Methods of Treating Adrenergic Dysregulation
    6.
    发明申请
    Extended Release Formulation and Methods of Treating Adrenergic Dysregulation 审中-公开
    延长释放制剂和治疗肾上腺素能调节的方法

    公开(公告)号：US20100172991A1

    公开(公告)日：2010-07-08

    申请号：US12645772

    申请日：2009-12-23

    申请人： Henry Joseph Horacek ,  Min Michael He ,  Moise A. Khayrallah

    发明人： Henry Joseph Horacek ,  Min Michael He ,  Moise A. Khayrallah

    IPC分类号： A61K9/14 ,  A61K31/4168 ,  C07D233/50 ,  A61P9/12 ,  A61P9/04 ,  A61P25/06 ,  A61P25/02 ,  A61P25/30 ,  A61P3/04 ,  A61P25/18

    CPC分类号： B65D77/0426

    摘要： A composition and method of treating adrenergic dysregulation by administering the composition is disclosed, wherein the composition comprises a α2-adrenergic receptor agonist; a pharmaceutically acceptable hydrophilic matrix and a release-retardant of a metal alkyl sulfate. In embodiments, the composition provides a sustained release of the agonist, wherein after administration of the composition no more than once about every 12 hours (e.g., no more than once about every 24 hours) to a subject having a steady state plasma concentration of the α2-adrenergic receptor agonist, the agonist's plasma concentration peak-to-trough ratio is no greater than about 1.9.

    摘要翻译： 公开了通过施用组合物治疗肾上腺素能失调的组合物和方法，其中所述组合物包含α2-肾上腺素能受体激动剂; 药学上可接受的亲水基质和金属烷基硫酸盐的释放阻滞剂。 在实施方案中，组合物提供激动剂的持续释放，其中在给予组合物不超过一次约每12小时一次（例如，每24小时不超过一次）给予具有稳态血浆浓度的受试者 α2-肾上腺素能受体激动剂，激动剂的血浆浓度峰 - 谷比不大于约1.9。

    EXTENDED RELEASE FORMULATION AND METHOD OF TREATING ADRENERGIC DYSREGULATION
    7.
    发明申请
    EXTENDED RELEASE FORMULATION AND METHOD OF TREATING ADRENERGIC DYSREGULATION 审中-公开
    扩展释放配方和治疗ADRENERGIC DYSREGULATION的方法

    公开(公告)号：US20090087490A1

    公开(公告)日：2009-04-02

    申请号：US12134444

    申请日：2008-06-06

    申请人： Henry Joseph Horacek ,  Min Michael He ,  Moise A. Khayrallah

    发明人： Henry Joseph Horacek ,  Min Michael He ,  Moise A. Khayrallah

    IPC分类号： A61K31/4168 ,  A61K9/00 ,  A61P25/00 ,  A61K47/38

    CPC分类号： A61K9/2018 ,  A61K9/2013 ,  A61K9/205 ,  A61K9/2054

    摘要： A composition and method of treating adrenergic dysregulation by administering the composition is disclosed, wherein the composition comprises a α2-adrenergic receptor agonist; a pharmaceutically acceptable hydrophilic matrix and a release-retardant of a metal alkyl sulfate. In embodiments, the composition provides a sustained release of the agonist, wherein after administration of the composition no more than once about every 12 hours to a subject having a steady state plasma concentration of the α2-adrenergic receptor agonist, the agonist's plasma concentration peak-to-trough ratio is no greater than about 1.9.

    摘要翻译： 公开了通过施用组合物治疗肾上腺素能失调的组合物和方法，其中所述组合物包含α2-肾上腺素能受体激动剂; 药学上可接受的亲水基质和金属烷基硫酸盐的释放阻滞剂。 在实施方案中，组合物提供激动剂的持续释放，其中在给予具有α2-肾上腺素能受体激动剂的稳态血浆浓度的受试者的组合物不超过一次的情况下，每12小时给予激动剂的血浆浓度峰 - 槽比不大于约1.9。

    Extended release formulation and method of treating adrenergic dysregulation
    9.
    发明授权
    Extended release formulation and method of treating adrenergic dysregulation 有权
    延长释放制剂和治疗肾上腺素能失调的方法

    公开(公告)号：US07884122B2

    公开(公告)日：2011-02-08

    申请号：US12615477

    申请日：2009-11-10

    申请人： Henry Joseph Horacek ,  Min Michael He ,  Moise A. Khayrallah

    发明人： Henry Joseph Horacek ,  Min Michael He ,  Moise A. Khayrallah

    IPC分类号： A01N43/50 ,  A61K31/415 ,  A61K9/22 ,  A61K9/14

    CPC分类号： A61K9/2018 ,  A61K9/2013 ,  A61K9/205 ,  A61K9/2054

    摘要： A composition and method of treating adrenergic dysregulation by administering the composition is disclosed, wherein the composition comprises a a2-adrenergic receptor agonist; a pharmaceutically acceptable hydrophilic matrix and a release-retardant of a metal alkyl sulfate. In embodiments, the composition provides a sustained release of the agonist, wherein after administration of the composition no more than once about every 12 hours to a subject having a steady state plasma concentration of the a2-adrenergic receptor agonist, the agonist's plasma concentration peak-to-trough ratio is no greater than about 1.9.

    摘要翻译： 公开了通过施用组合物治疗肾上腺素能失调的组合物和方法，其中所述组合物包含α1-肾上腺素能受体激动剂; 药学上可接受的亲水基质和金属烷基硫酸盐的释放阻滞剂。 在实施方案中，组合物提供激动剂的持续释放，其中在将组合物给予具有稳定的α2 - 肾上腺素能受体激动剂的稳态血浆浓度的受试者每12小时不超过一次的情况下，所述激动剂的血浆浓度峰 - 槽比不大于约1.9。